Specifications TableSubject area*Virology*More specific subject area*Virus diagnostics*Type of data*One Table and two graphs (Figures)*How data was acquired*Data were basically acquired by spectrophotometry using an ELISA plate reader - Multiskan™ GO Microplate Spectrophotometer (Thermo Fisher Scientific, USA). Recombinant proteins were obtained using ÄKTAprime plus (GE Healthcare, USA)*Data format*Analyzed data are shown*Experimental factors*Samples are crude human sera that were simply heated to eliminate complement factors. The ELISA\'s recombinant antigen was obtained by affinity chromatography and maintained in 6 M urea up to use.*Experimental features*The ELISA\'s recombinant antigen - the E2 protein from Chikungunya virus - was expressed in E. coli transformed cells and purified by affinity chromatography. The purified protein was used as the antigenic solid phase of the ELISA and was tested against a bank of characterized human sera, composed of Chikungunya-positive sera, Dengue-positive sera or Zika-positive sera. Sera that are negative for all viruses were also used.*Data source location*Minas Gerais State, Brazil.*Data accessibility*State if data is with this article.*Related research article*This data article is submitted as a companion paper to:*\
*Bagno, FF, Figueiredo, MM, Villarreal J, Pereira, GC, Godoi, LC, da Fonseca, FG. Undetected Chikungunya Virus Co-Infections in a Brazilian Region Presenting Hyper-Endemic Circulation of Dengue and Zika. J. Clin. Virol. In press.***Value of the Data**•This data provides details about the design and production of a recombinant Chikungunya virus protein (rCHIKp).•We describe the standardization of an in house ELISA using the rCHIKp as an antigen.•The developed ELISA presented the ability to distinguish chikungunya-positive human sera from virus-negative sera.•The ELISA was also able to efficiently distinguish patients that were seropositive for chikungunya from those that were seropositive for dengue or zika.

1. Data {#sec1}
=======

We design a synthetic gene coding for a recombinant *Chikungunya virus* protein (rCHIKp) to be used as an antigen in serologic assays. *In silico* analysis revealed that rCHIKp secondary structure has predominant coils and identified B lymphocyte epitopes in regions of structural disorder, which are advantageous for antigenic recognition. The overall antigenic prediction score was 0.53 (which suggests a probable efficient antigen). The gene was expressed in *E. coli* cells and purified by affinity chromatography. Coomassie Brilliant Blue staining showed the presence of rCHIKp with the predicted molecular mass (~∼~42 kDa). Next, we developed an In House Enzyme-Linked Immunosorbent Assay (ELISA) for the detection of immunoglobulin G (IgG) anti-CHIKV using the rCHIKp as the ELISA\'s antigenic solid phase. The rCHIKVp-based ELISA showed a sensitivity value of 95% and specificity of 96% ([Table 1](#tbl1){ref-type="table"}). No cross-reactivity was found against sera from Zika- (ZIKV) and Dengue- (DENV) positive patients ([Fig. 1](#fig1){ref-type="fig"}). The developed ELISA was used in the assessment of human patients suspected of arboviral infections in Minas Gerais State, Brazil [@bib1].Table 1Relative sensitivity and specificity of the rCHIKVp-based in house-Anti-CHIKV ELISA in comparison to a commercial kit (*Chikungunya IgG ELISA Euroimmun, Germany*).Table 1In house-Anti-CHIKV ELISANo. of pos.No. of neg.ParametersCommercial kitPos. (n = 71)683Sensitivity: 96%Neg. (n = 76)742Specificity: 97%Fig. 1Seroreactivity of the rCHIKVp using the developed indirect ELISA against Chikungunya-positive sera (CHIKV+) and virus-negative sera (CHIKV-/DENV-/ZIKV-). Potential cross reactivity with sera samples that were positive for co-circulating arboviruses were also tested: Dengue positive (DENV+) and Zika positive (ZIKV+) sera. A cut-off value of 0,279 was obtained, according to the Roc curve (inset).Fig. 1

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Design of the antigen gene {#sec2.1}
-------------------------------

CHIKV genome sequences deposited at GenBank were aligned using MEGA7 software [@bib2]. The selection criteria were: complete annotation of the genome and absence of indefinite nucleotides in the sequence. Brazilian (n = 42) and foreign samples belonging to the genotypes circulating in Brazil were used. Sequences belonged to the Asian genotype (n = 112) and East-Central South African (ECSA) genotype (n = 274). A consensus sequence was generated for each group (Group 1: Brazilian samples, Group 2: Asian genotype samples and Group 3: ECSA genotype samples). These consensual sequences were, then, compared to each other to generate a unique nucleotide sequence.

The gene sequence was codon-optimized for expression in *E. coli* by OptimumGene ™ - Codon Optimization software (Genescript). Transmembrane and hydrophobicity analyzes were performed using TMHMM (<http://www.cbs.dtu.dk/services/TMHMM/>) [@bib3] and Protscale -Expasy (<http://web.expasy.org/Protscale/>) [@bib4]. From these predictions, a cut-off point for the generation of the protein without its transmembrane domain was determined. The nucleotide sequence of the truncated protein-coding gene was commercially synthesized and subcloned into the pET-21 expression vector, which included a histidine tag to the construction.

2.2. In silico analysis {#sec2.2}
-----------------------

To evaluate the potential of our rCHIKVp as a diagnostic tool, the protein\'s predicted amino acid sequence was submitted to BepiPred (<http://www.cbs.dtu.dk/services/BepiPred/>) for the prediction of linear B cell epitopes [@bib5] and IUPred (<http://iupred.enzim.hu/>), for the prediction of intrinsic structural disorder, indicating absence of secondary structure and, consequently, regions of possible interaction with antibodies [@bib6]. The antigenicity of the designed protein was evaluated by the VexiJen V2.0 online server (<http://www.ddphpharmfac.net/vaxijen/VaxiJen/VaxiJen.html>) [@bib7].

2.3. Recombinant protein production {#sec2.3}
-----------------------------------

The pET-21 vector containing the gene of interest was used to transform *E. coli* BL21(DE3) strain by heat shock. Plasmid-positive clones were induced by IPTG and expression of the recombinant protein was optimized and analyzed by SDS-PAGE. The antigen was purified by affinity chromatography using nickel columns in an *ÄKTAprime plus system (GE Healthcare, USA)*.

2.4. In house *Anti*-Chikungunya virus ELISA {#sec2.4}
--------------------------------------------

The seroreactivity of the rCHIKVp was evaluated using a panel of sera samples from human patients, CHIKV seropositive or not, by an in-house indirect IgG ELISA. Strips of polystyrene microwells (Costar, USA) were coated overnight at 4 °C with 100 μl per well of rCHIKVp diluted in carbonate buffer (0.05 M, pH 9.6). Wells were washed five times with phosphate-buffered saline (PBS) containing 0.1% Tween20 (PBS-T) and blocked with 1% bovine serum albumin (BSA, SIGMA,USA) for 2 h at 25 °C. Then 100 μl of serum diluted in PBS-T was added and incubated for 1 hour at 37 °C. After five washes, we added 100 μl of horseradish peroxidase (HRP)-conjugated anti-human IgG goat immunoglobulin (Fapon, China), diluted at 1:100.000 in stabilizing diluent (MOSS, USA). Plates were incubated for 30 min at 37 °C, washed five times, and 100 μl of TMB (3,3′, 5,5; -tetramethylbenzidine, MOSS, USA) were added and incubated for further 15 min. Then, 100 μl of H~2~SO~4\ ,~ 0,5 M solution was add to the wells to stop the reaction. The plates were analyzed in a Microplate Reader at an optical density (O.D.) of 450 nm.

The optimal concentration of the recombinant rCHIKVp per plate well was determined based on a clear distinction of anti-CHIKV antibodies using positive and negative samples. We tested a range of 25--800 ng/well of rCHIKVp and sera dilutions ranging from 1:25 to 1:3200 ([Fig. 2](#fig2){ref-type="fig"}). The cut-off value was determined by ROC curve analysis, and an index (*I*) of each absorbance value of the patient sample over the value of cut-off was calculated, according to the equation:Fig. 2Standardization of in house anti-CHIKV ELISA IgG, with determination of the optimal sera dilution and antigen concentration.Fig. 2

*I* = *a*/*c*, where *a* is the absorbance of the patient sample and *c* is the cut-off value (0,279).

The data is classified as follows:*I* \< 0.9: negative0.9 ≤ *I* \< 1.1: borderline*I* ≥ 1.1: positive
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